Dexmedetomidine Hydrochloride · Regulatory label update

FDA supplemental approval: Dexmedetomidine Hydrochloride (Labeling)

U.S. Food and Drug Administration · July 8, 2026

Insufficient Information Why this matters to you Expert discussion

The material analysed did not support any firm read.

AI Summary

This is an FDA supplemental approval action for a labeling change to dexmedetomidine hydrochloride injectable (200 mcg base per 2 mL formulation) sponsored by Zydus Pharma, approved on 8 July 2026. The record does not contain clinical trial results, efficacy data, or comparative evidence and reflects only an administrative regulatory decision affecting labeling.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory labeling supplement, not a clinical trial; no efficacy, safety, or comparative trial data are reported. No safety or efficacy evidence supporting approval is presented in this record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of dexmedetomidine hydrochloride labeling; no clinical trial data or efficacy evidence reported in this regulatory action record.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-08

Formulation strength200 mcg base/2 mL (100 mcg base/mL)

Application numberANDA206798

Caveats

This is a regulatory labeling supplement, not a clinical trial; no efficacy, safety, or comparative trial data are reported.
No clinical outcomes, sample size, or population characteristics are provided.
The record does not indicate the nature of the labeling change or its clinical rationale.
No safety or efficacy evidence supporting approval is presented in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory labeling action; no study design applicable.

Directness

insufficient

No clinical outcomes or efficacy data reported in this record.

Consistency

insufficient

Single regulatory action; no comparative or replication data included.

Risk of bias

insufficient

Regulatory approval record does not include trial methodology or bias assessment.

Sample adequacy

insufficient

No clinical trial sample size or population data reported.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA206798. This is a regulatory action record, not a clinical study. Brand name: DEXMEDETOMIDINE HYDROCHLORIDE. Active ingredient: DEXMEDETOMIDINE HYDROCHLORIDE. Sponsor: ZYDUS PHARMS. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-08. Products: DEXMEDETOMIDINE HYDROCHLORIDE, INJECTABLE, INJECTION, DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Zydus PharmsDexmedetomidine Hydrochloride